Patents by Inventor Marta Dabros

Marta Dabros has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS
    Publication number: 20190040043
    Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides crystalline forms, pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: July 31, 2018
    Publication date: February 7, 2019
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: ERIK FENSTER, TOM M. LAM, MANDY LOO, ROBERT MURRAY MCKINNELL, ANTHONY FRANCESCO PALERMO, DIANA JIN WANG, BREENA FRAGA, JERRY NZEREM, MARTA DABROS, VENKAT R. THALLADI, MIROSLAV RAPTA
  • JAK kinase inhibitor compounds for treatment of respiratory disease
    Patent number: 10183942
    Abstract: The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: January 22, 2019
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Noah Benjamin, Marta Dabros, Venkat R. Thalladi
  • JAK Kinase Inhibitor Compounds for Treatment of Respiratory Disease
    Publication number: 20180319796
    Abstract: The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: July 18, 2018
    Publication date: November 8, 2018
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Noah Benjamin, Marta Dabros, Venkat R. Thalladi
  • FUSED IMIDAZO-PIPERIDINE JAK INHIBITOR COMPOUND
    Publication number: 20180311255
    Abstract: The invention provides a compound of formula 1 or a pharmaceutically-acceptable salt thereof, that is useful as a JAK inhibitor. The invention also provides crystalline forms of the compound, pharmaceutical compositions comprising the compound, methods of using the compound to treat diseases amenable to a JAK inhibitor, and processes and intermediates useful for preparing the compound.
    Type: Application
    Filed: April 30, 2018
    Publication date: November 1, 2018
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: PAUL R. FATHEREE, LAN JIANG, ROBERT MURRAY MCKINNELL, VENKAT R. THALLADI, HAO ZHANG, MARTA DABROS, JERRY NZEREM, NOAH BENJAMIN, MELANIE A. KLEINSCHEK, GLENN D. CRATER
  • CRYSTALLINE FORMS OF A JAK INHIBITOR COMPOUND
    Publication number: 20180311223
    Abstract: The present invention provides crystalline hydrates of the oxalate and succinate salts of 5-ethyl-2-fluoro-4-(3-(5-(1-methylpiperidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl)phenol. The invention also provides pharmaceutical compositions comprising such crystalline hydrates, methods of using such crystalline hydrates to treat respiratory and other diseases, and processes useful for preparing such crystalline oxalate and succinate hydrates.
    Type: Application
    Filed: April 30, 2018
    Publication date: November 1, 2018
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: MARTA DABROS, VENKAT R. THALLADI, JERRY NZEREM, MELANIE A. KLEINSCHEK, GLENN D. CRATER
  • Crystalline forms of a factor XIa inhibitor
    Patent number: 9920034
    Abstract: The instant invention provides crystalline forms of (S,E)-4-(2-(3-(3-chloro-2-fluoro-6-(1H-tetrazol-1-yl)phenyl)acryloyl)-5-(4-methyl-2-oxopiperazin-1-yl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamido)benzoic acid and its solvates thereof; processes for the production of such crystalline forms; pharmaceutical compositions comprising such crystalline forms; and methods of treating thromboembolic disorders with such crystalline forms or such pharmaceutical compositions.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: March 20, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Marta Dabros, Chenkou Wei
  • JAK Kinase Inhibitor Compounds for Treatment of Respiratory Disease
    Publication number: 20170121327
    Abstract: The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: November 2, 2016
    Publication date: May 4, 2017
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Paul R. Fatheree, John R. Jacobsen, Anne-Marie Beausoleil, Gary E. Brandt, Melissa Fleury, Lan Jiang, Cameron Smith, Steven D.E. Sullivan, Lori Jean Van Orden, Pierre-Jean Colson, Gene Timothy Fass, Miroslav Rapta, Noah Benjamin, Marta Dabros, Venkat R. Thalladi
  • SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS
    Publication number: 20160318904
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.
    Type: Application
    Filed: July 8, 2016
    Publication date: November 3, 2016
    Inventors: Michael J. Orwat, Donald J.P. Pinto, Leon M. Smith, II, Shefali Srivastava, Marta Dabros, Chenkou Wei
  • CRYSTALLINE FORMS OF A FACTOR XIA INHIBITOR
    Publication number: 20150266855
    Abstract: The instant invention provides crystalline forms of (S,E)-4-(2-(3-(3-chloro-2-fluoro-6-(1H-tetrazol-1-yl)phenyl)acryloyl)-5-(4-methyl-2-oxopiperazin-1-yl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamido)benzoic acid and its solvates thereof; processes for the production of such crystalline forms; pharmaceutical compositions comprising such crystalline forms; and methods of treating thromboembolic disorders with such crystalline forms or such pharmaceutical compositions.
    Type: Application
    Filed: October 11, 2013
    Publication date: September 24, 2015
    Inventors: Marta Dabros, Chenkou Wei
  • Tetrahydronaphthalenyl compounds useful as sipi agonists
    Patent number: 9115054
    Abstract: Disclosed are compounds of Formula (I) and/or a salt thereof; wherein R is —OH or —OP(O)(OH)2. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: August 25, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: T. G. Murali Dhar, Hai-Yun Xiao, Alaric J. Dyckman, Eric J. Chan, Marta Dabros, Daniel Richard Roberts
  • BICYCLIC COMPOUNDS
    Publication number: 20140235591
    Abstract: Disclosed are compounds of Formula (I) and/or a salt thereof; wherein R is —OH or —OP(O)(OH)2. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Application
    Filed: February 20, 2014
    Publication date: August 21, 2014
    Inventors: T. G. Murali Dhar, Hai-Yun Xiao, Alaric J. Dyckman, Eric J. Chan, Marta Dabros, Daniel Richard Roberts
  • SELECTIVE GROWTH OF STABLE POLYMORPHS
    Publication number: 20110009623
    Abstract: Methods and an apparatus for producing stable crystal polymorphs are provided. Inner surfaces of glass vials with a concave bottom topography are coated with nonstick compounds to select for nucleation of stable polymorphs.
    Type: Application
    Filed: March 20, 2007
    Publication date: January 13, 2011
    Applicant: Worcester Polytechnic Institute
    Inventors: Jason R. Cox, Marta Dabros, Venkat R. Thalladi